Stem Cell Therapeutics Announces Issuance of Additional US Patent for Use of Prolactin
May 19 2009 - 7:30AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) has been
issued United States Patent No. 7,534,765, entitled "Pregnancy
Induced Oligodendrocyte Precursor Cell Proliferation Regulated by
Prolactin". This patent, issued today, covers methods of using of
prolactin for enhancing the formation of oligodendendrocytes in
vivo, such as to treat diseases associated with loss of
myelin-producing oligodendrocytes (white matter diseases).
Dr. Alan Moore, President and CEO, commented as follows:
"This patent bolsters our intellectual property position around
the use of prolactin for treating demyelinating neurodegenerative
diseases such as multiple sclerosis ("MS") in which the myelin
sheath surrounding the axon of neurons is damaged. The finding that
prolactin enhances oligodendrocyte production and remyelination is
what stimulated the development of our NTx�-488 program for MS,
with preclinical studies being completed in preparation for Phase
II clinical trials.
Importantly, as covered by other SCT patents, prolactin also
stimulates neural stem cell proliferation and neurogenesis.
Prolactin is therefore expected to repair both the myelin damage
and the neuronal damage in MS, which is necessary for full
functional recovery, and makes prolactin a unique MS drug
candidate."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. The
Company's extensive patent portfolio of owned and licensed
intellectual property supports the potential expansion into future
clinical programs in numerous neurological diseases such as
traumatic brain injury, multiple sclerosis Huntington's disease,
Alzheimer's disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Sep 2023 to Sep 2024